Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TM471-1 capsules in chronic spontaneous urticaria
CTR20254813Phase 2Active
- Sponsor
- Zhiwei Biopharma
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TM471-1 in chronic idiopathic urticaria (CIU), sponsored by Zhiwei Biopharma. Started Dec 2025; status: active.
02
Drugs
TM471-1
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20254813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254813.